The low proportion of insulin pump therapy in people with type 2 diabetes (0.7 %) is in line with the results of an study of diabetologists in 2023 regarding new technologies in their facilities, according to which a pump is only used in around 0.4 % of people with type 2 diabetes [50]. This evidence concerns the gene INS and type 2 diabetes mellitus.